Table 2

Platelet response of enrolled patients

Patient IDVisits as responder, %*Visits with plt count > 30 × 109/L, %Visits with plt count > 50 × 109/L, %Visits IVIg given, %Baseline plt count, ×109/LMax plt count, ×109/LMed plt count, ×109/L§No. of dose changesSteroids tapered
Maintained response
    1100100100064582160No
    21001001000121541000Yes
    31001001000221591061Yes
    495100950221901041Yes
    594100940161971270Yes
    6919595523943170No
    7779658020111550No
    8686845011186431No
    Median9196940161901040
Nonmaintained response#
    9233217412195234No
    1025453520698144Yes
    11247224028158364No
    12204914022222274No
    Median244721217177254
No response**
    13060781116104No
    14000731813122No
    1500001615140No
    160002531390No
    Median000491414111
  • Subjects 1-3, 5, 6, 8-10, and 12-14 had undergone splenectomy; subjects 6, 8, 9, 13, and 16 had failed a thrombopoietic agent.

  • Plt indicates platelet; max, maximum; and med, median.

  • * Responder was defined as increase in platelet count by more than 20 × 109/L to greater than 30 × 109/L.

  • Baseline value is within 1 month before first dose of study drug.

  • Max value is while on study drug with no IVIg treatment in preceding 2 weeks.

  • § Median value is while on study drug with no IVIg treatment in preceding 2 weeks.

  • Steroids include prednisone, methylprednisolone, and danazol.

  • Platelets increased by greater than 20 × 109/L to greater than 30 × 109/L for at least 66% of visits.

  • # Platelets increased by greater than 20 × 109/L to greater than 30 × 109/L for less than 66% of study visits.

  • ** Platelets did not increase by greater than 20 × 109/L to greater than 30 × 109/L.